Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant.

about

Surgical Interventions for Organ and Limb Ischemia Associated With Primary and Secondary Antiphospholipid Antibody Syndrome With Arterial Involvement.

P2860

Q47636314-F496BF3E-8194-45E6-B46F-BA328DB31003

P2860

Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant.

Item

http://www.wikidata.org/entity/Q36303250

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Cardiovascular risk factors ar ...... with the lupus anticoagulant.

@ast

Cardiovascular risk factors ar ...... with the lupus anticoagulant.

@en

type

Item

label

Cardiovascular risk factors ar ...... with the lupus anticoagulant.

@ast

Cardiovascular risk factors ar ...... with the lupus anticoagulant.

@en

prefLabel

Cardiovascular risk factors ar ...... with the lupus anticoagulant.

@ast

Cardiovascular risk factors ar ...... with the lupus anticoagulant.

@en

P1476

Cardiovascular risk factors ar ...... with the lupus anticoagulant.

@en

P2093

Florian Posch

http://www.w3.org/2001/XMLSchema#string

Jacob H Rand

http://www.w3.org/2001/XMLSchema#string

Johanna Gebhart

http://www.w3.org/2001/XMLSchema#string

Silvia Koder

http://www.w3.org/2001/XMLSchema#string

Vittorio Pengo

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

Antiphospholipid Antibodies and Recurrent Thrombotic Events: Persistence and Portfolio.

Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions.

Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.

Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients.

Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study.

Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature.

Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. The TRIPOD Group.

Antiphospholipid syndrome: multiple mechanisms.

P2888

s12916-017-0807-7

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12916-017-0807-7

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ingrid Pabinger

Peter Quehenberger

Cihan Ay

P577

2017-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084251043

http://www.w3.org/2001/XMLSchema#string

P698

28279213

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation

P932

5345189

http://www.w3.org/2001/XMLSchema#string

Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant.

about

P2860

P2860

Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P921

P932